By Josh Beckerman
Shares of Tivic Health Systems rose after it discussed briefings provided to senior leadership at the White House and Food and Drug Administration about potential military and defense uses of its product candidates.
The stock was recently up 104% to $7.13 Tuesday. Its intraday range was $6.61 to $13.23. Volume was more than 30.8 million shares, compared with a 65-day average of 1.2 million. Shares are up about 20% this year.
The White House briefing involved the company's TLR5 program, including lead product candidate Entolimod, and the need for advanced treatments for acute radiation syndrome, Tivic said.
The meeting with FDA leadership explored expedited pathways to approval for Entolimod and Entolasta, the company said.
Tivic Chief Operating Officer and President Michael Handley said, "We believe that Entolimod, in particular, is well positioned to fill a critical gap in treating exposure to ionizing radiation and offers several potential advantages over existing approved drugs in the category."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
April 22, 2025 13:11 ET (17:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。